{"protocolSection":{"identificationModule":{"nctId":"NCT06472245","orgStudyIdInfo":{"id":"OSE2101C302"},"organization":{"fullName":"OSE Immunotherapeutics","class":"INDUSTRY"},"briefTitle":"Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor","officialTitle":"A Randomised, Open-label, Phase 3 Trial Comparing the Efficacy and Safety of OSE2101 Versus Docetaxel in HLA-A2 Positive Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) With Secondary Resistance to Immune Checkpoint Inhibitor","acronym":"ARTEMIA"},"statusModule":{"statusVerifiedDate":"2024-06","overallStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-06-30","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2027-12-15","type":"ESTIMATED"},"completionDateStruct":{"date":"2028-12-15","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-06-07","studyFirstSubmitQcDate":"2024-06-21","studyFirstPostDateStruct":{"date":"2024-06-25","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-06-21","lastUpdatePostDateStruct":{"date":"2024-06-25","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"OSE Immunotherapeutics","class":"INDUSTRY"},"collaborators":[{"name":"Exystat","class":"OTHER"},{"name":"Genome Diagnostics (GenDx)","class":"UNKNOWN"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":true,"isUnapprovedDevice":true},"descriptionModule":{"briefSummary":"Multicenter, randomized (2:1), open-label phase 3 study in HLA-A2 positive patients with squamous and non-squamous metastatic NSCLC with ICI secondary resistance.\n\nPatients will be randomized into 2 arms (randomization 2:1): experimental Arm A with OSE2101 monotherapy or control Arm B SoC with docetaxel monotherapy. Stratification factors will be histology (squamous versus non squamous) and ECOG Performance Status (0 versus 1)."},"conditionsModule":{"conditions":["Patients With Non-Small Cell Lung Cancer"],"keywords":["Immune Checkpoint Inhibitor","Cancer vaccine","Non-Small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":363,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Arm A: OSE2101","type":"EXPERIMENTAL","description":"Unit dose: 1 mL corresponding to a total of 5 mg of the combination of peptides Mode/Route: Subcutaneous injection Regimen: One injection every three weeks for six cycles, then every eight weeks for the remainder of year one and, finally every twelve weeks until the end of second year.","interventionNames":["Drug: OSE2101","Device: NGS HLAA2 assay"]},{"label":"Arm B: Docetaxel","type":"ACTIVE_COMPARATOR","description":"Unit dose: 75 mg/m2 Mode/Route: Intravenous infusion over 1 hour Regimen: One infusion every three weeks.","interventionNames":["Drug: Docetaxel","Device: NGS HLAA2 assay"]},{"label":"GenDx CDx Tedopi","type":"OTHER","description":"System of qualitative companion diagnostic devices, consisting of a polymerase chain reaction (PCR) assay Amp-HLA-A-CDx Tedopi, a DNA library preparation assay, LFK-CDx Tedopi and the software NGSengine-CDx Tedopi.","interventionNames":["Device: NGS HLAA2 assay"]}],"interventions":[{"type":"DRUG","name":"OSE2101","description":"OSE2101 is a peptidic cancer vaccine composed of nine epitopes restricted to HLA-A2 phenotype targeting the tumor associated antigens of P53, HER-2, CEA, MAGE-2 and MAGE-3, and one pan-HLA DR binding epitope (PADRE), all epitopes emulsified in Montanide ISA 51TM adjuvant.","armGroupLabels":["Arm A: OSE2101"]},{"type":"DRUG","name":"Docetaxel","description":"Docetaxel is an antineoplastic agent that acts by disrupting the microtubular network in cells that is essential for mitotic and interphase cellular functions.","armGroupLabels":["Arm B: Docetaxel"]},{"type":"DEVICE","name":"NGS HLAA2 assay","description":"Amp-HLA-A-CDx Tedopi for amplification of human genomic DNA (gDNA), LFK-CDx Tedopi kit (library full kit) for library preparation, NGSengine-CDx Tedopi software for analysis of NGS data files.","armGroupLabels":["Arm A: OSE2101","Arm B: Docetaxel","GenDx CDx Tedopi"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"OS defined as time from randomization to death","description":"OS defined as time from randomization to death of any cause, censored until the data analysis cut-off date","timeFrame":"From randomization date through study completion, an average of 3 years"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Male or female, aged ≥ 18 years\n2. Patients expressing HLA-A2 phenotype in blood by pre-screening central laboratory\n3. Patients with histologically or cytologically squamous or non-squamous documented NSCLC, metastatic stage at study entry, not eligible for definite surgery or radiation, without EGFR, ALK and ROS1 gene alterations eligible for targeted therapy; other sensitizing mutations known to be immunosensitive are eligible in case of lack of local access to targeted therapy (i.e.; KRAS G12C and BRAF mutations) after Sponsor's agreement\n4. Patients with secondary resistance to ICI;\n\nOther inclusion and exclusion criteria will apply per protocol.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Caroline Chevalier, MSc, MPH","role":"CONTACT","phone":"+33 630 842 002","email":"caroline.chevalier@ose-immuno.com"},{"name":"Bérangère Vasseur, MD","role":"CONTACT","phone":"+33 676 448 160","email":"berangere.vasseur@ose-immuno.com"}],"locations":[{"facility":"Georgetown Lombardi Comprehensive Cancer Center","city":"Washington","state":"District of Columbia","zip":"20007","country":"United States","geoPoint":{"lat":38.89511,"lon":-77.03637}},{"facility":"Alliance for Multispecialty Research (AMR) - Kansas City Oncology","city":"Merriam","state":"Kansas","zip":"66204","country":"United States","geoPoint":{"lat":39.02362,"lon":-94.69357}},{"facility":"NHO Revive Research Institute LLC","city":"Lincoln","state":"Nebraska","zip":"68506","country":"United States","geoPoint":{"lat":40.8,"lon":-96.66696}},{"facility":"Optum Medical Care - Carmel/Brewster Campus","city":"Brewster","state":"New York","zip":"10509-2338","country":"United States","geoPoint":{"lat":41.39732,"lon":-73.61707}},{"facility":"Optum Medical Care - Fishkill Westage Campus","city":"Fishkill","state":"New York","zip":"12524","country":"United States","geoPoint":{"lat":41.53565,"lon":-73.89903}},{"facility":"Optum Hematology Oncology - Lake Success","city":"Lake Success","state":"New York","zip":"11042","country":"United States","geoPoint":{"lat":40.77066,"lon":-73.71763}},{"facility":"Optum Medical Care - Mount Kisco Campus 90","city":"Mount Kisco","state":"New York","zip":"10549","country":"United States","geoPoint":{"lat":41.20426,"lon":-73.72708}},{"facility":"Optum Medical Care - Poughkeepsie","city":"Poughkeepsie","state":"New York","zip":"12601","country":"United States","geoPoint":{"lat":41.70037,"lon":-73.92097}},{"facility":"Brooklyn Radiation Oncology","city":"Richmond Hill","state":"New York","zip":"11418","country":"United States","geoPoint":{"lat":40.69983,"lon":-73.83125}},{"facility":"Bon Secours Hematology and Oncology","city":"Greenville","state":"South Carolina","zip":"29607","country":"United States","geoPoint":{"lat":34.85262,"lon":-82.39401}}]},"referencesModule":{"references":[{"pmid":"37704166","type":"RESULT","citation":"Besse B, Felip E, Garcia Campelo R, Cobo M, Mascaux C, Madroszyk A, Cappuzzo F, Hilgers W, Romano G, Denis F, Viteri S, Debieuvre D, Galetta D, Baldini E, Razaq M, Robinet G, Maio M, Delmonte A, Roch B, Masson P, Schuette W, Zer A, Remon J, Costantini D, Vasseur B, Dziadziuszko R, Giaccone G; ATALANTE-1 study group. Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1. Ann Oncol. 2023 Oct;34(10):920-933. doi: 10.1016/j.annonc.2023.07.006. Epub 2023 Sep 11."}]},"ipdSharingStatementModule":{"ipdSharing":"UNDECIDED"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-07-01"},"conditionBrowseModule":{"meshes":[{"id":"D000008175","term":"Lung Neoplasms"},{"id":"D000002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D000012142","term":"Respiratory Tract Neoplasms"},{"id":"D000013899","term":"Thoracic Neoplasms"},{"id":"D000009371","term":"Neoplasms by Site"},{"id":"D000009369","term":"Neoplasms"},{"id":"D000008171","term":"Lung Diseases"},{"id":"D000012140","term":"Respiratory Tract Diseases"},{"id":"D000002283","term":"Carcinoma, Bronchogenic"},{"id":"D000001984","term":"Bronchial Neoplasms"}],"browseLeaves":[{"id":"M11172","name":"Lung Neoplasms","asFound":"Lung Cancer","relevance":"HIGH"},{"id":"M5546","name":"Carcinoma, Non-Small-Cell Lung","asFound":"Non-Small Cell Lung Cancer","relevance":"HIGH"},{"id":"M12307","name":"Neoplasm Metastasis","relevance":"LOW"},{"id":"M5534","name":"Carcinoma","relevance":"LOW"},{"id":"M14979","name":"Respiratory Tract Neoplasms","relevance":"LOW"},{"id":"M16658","name":"Thoracic Neoplasms","relevance":"LOW"},{"id":"M11168","name":"Lung Diseases","relevance":"LOW"},{"id":"M14977","name":"Respiratory Tract Diseases","relevance":"LOW"},{"id":"M5540","name":"Carcinoma, Bronchogenic","relevance":"LOW"},{"id":"M5260","name":"Bronchial Neoplasms","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC04","name":"Neoplasms"},{"abbrev":"BC08","name":"Respiratory Tract (Lung and Bronchial) Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000077143","term":"Docetaxel"}],"ancestors":[{"id":"D000000970","term":"Antineoplastic Agents"},{"id":"D000050257","term":"Tubulin Modulators"},{"id":"D000050256","term":"Antimitotic Agents"},{"id":"D000050258","term":"Mitosis Modulators"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"}],"browseLeaves":[{"id":"M1668","name":"Docetaxel","asFound":"Physical","relevance":"HIGH"},{"id":"M2342","name":"Immune Checkpoint Inhibitors","relevance":"LOW"},{"id":"M17360","name":"Vaccines","relevance":"LOW"},{"id":"M254598","name":"Monatide (IMS 3015)","relevance":"LOW"},{"id":"M26197","name":"Tubulin Modulators","relevance":"LOW"},{"id":"M26196","name":"Antimitotic Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"ANeo","name":"Antineoplastic Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}